CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

ICU Medical Q3 results beat estimates on Infusion Systems

By Reuters News


Overview

  • U.S. medical device maker's Q3 revenue rose yr/yr, beating analyst expectations

  • Adjusted EPS for Q3 beat analyst expectations

  • Company reaffirmed 2026 guidance, expects results at high end of range


Outlook

  • ICU Medical expects FY 2026 results at high end of prior guidance range

  • Company maintains FY 2026 GAAP net income guidance of $73 mln to $83 mln

  • ICU Medical sees FY 2026 adjusted diluted EPS of $8.60 to $9.00


Result Drivers

  • INFUSION SYSTEMS - Co said Q3 results were driven by better-than-expected performance in Infusion Systems

  • PRODUCT LINE PERFORMANCE - Co reported yr/yr revenue growth in Consumables and Infusion Systems, offset by decline in Vital Care

  • GROSS MARGIN IMPROVEMENT - Co attributed higher Q3 gross margin to improved product mix and operational efficiencies


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$560.44 mln

$552.07 mln (7 Analysts)

Q3 Adjusted EPS

Beat

$2.44

$2.14 (7 Analysts)

Q3 Adjusted EBITDA

Beat

$113.91 mln

$106.47 mln (7 Analysts)

Q3 Gross Profit

$234.75 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for ICU Medical, Inc. is $195.00, about 13% above its November 4 closing price of $172.62

  • The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 19 three months ago


Reuters Recommended Reads

  • Nov 5 - InfuSystem beats Q3 profit estimates on oncology, wound care growth

  • Nov 5 - Teleflex Q3 revenue slightly beats estimates

  • Nov 3 - Strata Critical Medical Q3 revenue beats estimates; announces buyback


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.